Research and Markets (http://www.researchandmarkets.com/research/9bp37x/epicast_report) has announced the addition of the "EpiCast Report: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Epidemiology Forecast to 2024" report to their offering.

The Methicillin-Resistant Staphylococcus aureus (MRSA) EpiCast Report provides an overview of the risk factors and global trends of MRSA in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). provides an overview of the risk factors, comorbidities, and the global and historical trends for MRSA in the 7MM and includes a 10-year epidemiological forecast for the hospitalized incident cases of MRSA, segmented by sex, age, infection site (pneumonias, SSTIs, and bloodstream infections [BSIs]), and case definition (HA-MRSA and CA-MRSA), in these markets.

The MRSA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

• Develop business strategies by understanding the trends shaping and driving the global MRSA market.
• Quantify patient populations in the global MRSA market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MRSA therapeutics in each of the markets covered.
• Identify the percentage of MRSA hospitalized incident cases by infection site and case definition.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global Trends

3.4 Forecast Methodology

3.5 Epidemiological Forecast for MRSA (2014-2024)

3.6 Discussion

4 Appendix

For more information visit http://www.researchandmarkets.com/research/9bp37x/epicast_report

View source version on businesswire.com: http://www.businesswire.com/news/home/20151201005807/en/